Last reviewed · How we verify
Atorvastatin-esomeprazole
This combination drug lowers cholesterol by inhibiting HMG-CoA reductase (atorvastatin) while reducing gastric acid secretion by blocking the proton pump (esomeprazole).
This combination drug lowers cholesterol by inhibiting HMG-CoA reductase (atorvastatin) while reducing gastric acid secretion by blocking the proton pump (esomeprazole). Used for Hyperlipidemia with concurrent need for gastric acid suppression, Cardiovascular disease prevention in patients at risk for statin-induced gastrointestinal adverse effects.
At a glance
| Generic name | Atorvastatin-esomeprazole |
|---|---|
| Sponsor | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec |
| Drug class | Statin + proton pump inhibitor combination |
| Target | HMG-CoA reductase; H+/K+-ATPase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Atorvastatin is a statin that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol and triglycerides. Esomeprazole is a proton pump inhibitor that suppresses gastric acid production by irreversibly blocking the H+/K+-ATPase pump in parietal cells. The combination is designed to provide cardiovascular protection while mitigating gastrointestinal side effects associated with statin therapy.
Approved indications
- Hyperlipidemia with concurrent need for gastric acid suppression
- Cardiovascular disease prevention in patients at risk for statin-induced gastrointestinal adverse effects
Common side effects
- Headache
- Myalgia
- Diarrhea
- Abdominal pain
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: